Verseon delivers pharmaceutical solutions using proprietary, computer-driven drug discovery platform technology. Through scientific advancements in physics- and chemistry-based modeling, Verseon’s gol is to address the cycle of slow and derivative pharmaceutical developments to create truly novel molecular entities. We innovate beyond the bounds of the known and design, test, and synthesize never-been-seen molecules that may soon become life-changing drugs. We began our mission in 2002 and since have built a proprietary platform that identifies novel potential therapeutics faster and more inexpensively than anyone in the industry. We are changing the way that drugs are made atom by atom. We are currently making great strides in cardiovascular diseases, macular degeneration, oncology, metabolic disorders, and mutation-resistant antivirals with over a dozen drug candidates in active development and one completing Phase 1 clinical trials.
Looking for a particular Verseon employee's phone or email?
The Verseon annual revenue was $750000 in 2026.
Adityo Prakash is the CEO of Verseon.
17 people are employed at Verseon.
Verseon is based in Fremont, California.
The NAICS codes for Verseon are [3254, 325, 32, 32541].
The SIC codes for Verseon are [28, 283].